ATLANTA– Hightop Health, a premier outpatient mental health platform, today announced the appointment of Carol Vallone as its Independent Board Director.
Hightop announced its launch in October 2023, along with the acquisition of its foundational practice, Psych Atlanta. With its launch, Hightop aimed to gather the best minds in the industry to speak into Hightop’s strategy and approach, including a Board of Directors and Clinical Advisory Board, with Carol Vallone being its first Independent Board Director. Vallone’s background is rooted in creating innovative models where technology, data, and analytics produce positive outcomes across multiple industries, particularly in mental healthcare. Her work and partnership with clinical leaders paired with her understanding of the behavioral health industry lends itself to furthering the Hightop mission.
Hightop partners with distinguished practices that specialize in high acuity and complex treatment leveraging longstanding and novel modalities, while offering a comprehensive continuum of care approach that ensures patients receive the highest quality care on a timely basis. The company accomplishes this mission with regionally focused, clinician-centric strategy, a mission Vallone is not only aligned with but to which she brings extensive experience and expertise.
“Hightop’s commitment to building a clinician-centric culture is largely why I was interested in joining its Board,” said Vallone. “Our ultimate goal is to utilize integrated, evidence-based care to improve patient outcomes, and the key first step is by truly valuing clinicians.”
Vallone is a seasoned CEO and board member who has successfully launched, scaled and sold multiple companies. In addition to serving on the Hightop Board, she also currently serves as chair of the Board of Trustees for McLean Hospital, the #1 ranked psychiatric hospital in America, according to U.S. News & World Report, and the largest psychiatric affiliate of Harvard Medical School. Vallone is also a trustee for the Mass General Brigham (MGB) integrated healthcare system and serves on the MGB system finance committee. Alongside her non-profit board service, Vallone is actively serving on multiple public and private boards, including MindMedicine, a clinical stage biopharmaceutical company focusing on brain health disorders, and Ria Health, an organization offering online, evidence-based treatment for alcohol use disorders. Through these roles, she brings in-depth understanding on the latest developments in the field to best serve critical patient needs at Hightop Health and beyond.
“Carol’s experience is off the charts invaluable to us as we expand,” said Rob Butler, CEO of Hightop Health. “Her background in mental healthcare paired with her operational savvy creates the perfect combination of experience for us to leverage as we build the key foundational cornerstones of Hightop.”
